Climb Bio, Inc. CLYM
Climb Bio, Inc. (Nasdaq: CLYM) is a cardio-renal-metabolic drug developer. Its lead program, budoprutug, is in Phase 2 for primary membranous nephropathy. Its next catalyst on record is budoprutug (ITP): ASH Annual Meeting presentation with additional Phase 1b data including 500 mg and 1000 mg cohorts (December 2026).
Upcoming catalysts
- December 2026budoprutug (ITP) — ASH Annual Meeting presentation with additional Phase 1b data including 500 mg and 1000 mg cohorts
we will present additional data from the ongoing Phase 1b trial, including from the 500 mg and 1000 mg dose cohorts at the American Society of Hematology (ASH) Annual Meeting in December 2026
Next further out: CLYM116 — Initial data from Mabworks NAVIGATE-2 Phase 2 trial (H1 2027). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| budoprutug | primary membranous nephropathy (pMN) | antibody | Phase 2 |
| budoprutug | immune thrombocytopenia (ITP) | antibody | Phase 1 |
| budoprutug | systemic lupus erythematosus (SLE) | antibody | Phase 1 |
| budoprutug SC (subcutaneous formulation) | autoimmune diseases | antibody | Phase 1 |
| CLYM116 | immunoglobulin A nephropathy (IgAN) | antibody | Phase 1 |
Recent results and decisions
- Nov 5, 2026positive CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose.
Across both studies, PK was linear, with no target-mediated drug disposition (TMDD) observed across the effective dose range, and >90% free APRIL suppression was sustained through 12 weeks following a single SC dose of ≥480 mg.
Filing - Nov 5, 2026started Climb Bio initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN.
Initiated dosing in NAVIGATE-2 Phase 2 trial in IgA nephropathy (IgAN); enrollment ongoing.
Filing - Nov 5, 2026positive Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks.
At Week 12, the 200 mg cohort demonstrated B-cell depletion, reductions in PLA2R antibody levels, and immunologic remission.
Filing
8 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.